Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Mark Frattini, MD, PhD
Email
mgf2122@columbia.edu

Dr. Mark G. Frattini is an Associate Professor of Medicine and Director of Research for the Hematologic Malignancies Section in the Hematology/Oncology Division at the Columbia University Medical Center. Previously, Dr. Frattini was a member of the Leukemia Service and Experimental Therapeutics Center at Memorial Sloan-Kettering for almost 11 years. He is a medical oncologist who specializes in the treatment of adult patients with acute and chronic leukemias, myelodisplastic syndromes, and myeloproliferative disorders.

Dr. Frattini's laboratory research focuses on new drug development for acute and chronic leukemias with a special interest in small molecule inhibitors of cell cycle regulated kinases as therapeutic targets. He has discovered a small molecule inhibitor of the cdc7 kinase that is currently in clinical development with a plan for Phase I clinical studies for patients with relapsed and/or chemotherapy-refractory leukemia in 2013. In addition, Dr. Frattini's research involves the development of methods to more precisely determine patient-specific response to various chemotherapeutic agents with a plan to translate this technology into the clinical setting and provide a more personalized approach to therapy for patients with these malignant diseases.

Dr. Frattini has lectured at national and international meetings and has published in various scientific journals, including Blood, Cell, EMBO, JNCCN, Journal of Biological Chemistry, Science, and Proceedings of the National Academy Sciences USA. He received his MD. and PhD in Biochemistry and Molecular Biology from The University of Chicage and completed his fellowship training in medical oncology at The Johns Hopkins Hospital.


Clinical Studies Managed By Dr. Frattini:
More InfoTitleSponsorIRB Number
DetailsA study for patients with Acute Myelogenous Leukemia using study drug ABT-199AbbVie IncAAAO1055
DetailsA study for patients with MDS, Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (MDS) using study drug pevonedistatMillennium Pharmaceuticals, Inc.AAAQ7445
DetailsA study for patients with myelodysplastic syndrome (MDS) using study drug venetoclaxAbbVieAAAR1076
DetailsA study for patients with Myelodysplastic Syndromes (MDS) using study drug VenetoclaxAbbVieAAAR1077
DetailsA study for patients with acute myeloid leukemia using study drug Venetoclax in combination with AzacitidineAbbVie, Inc. EntireAAAR1251